Arana expands clinical research
Monday, 28 July, 2008
Arana Therapeutics (ASX: AAH) has appointed former Quintiles executive Dr Alan Scott as its new vice president of clinical research.
The Sydney-headquartered biotech, the result of a merger between Peptech and EvoGenix last year, is commencing several new clinical trials in the next 18 months.
Arana's next scheduled clinical trial will be a Phase II rheumatoid arthritis dose-ranging study for its leading anti-inflammatory compound ART621, which is expected to start in the fourth quarter of this year.
Scott holds a PhD from Glasgow University, did a post-doc in biochemistry at Oxford and has held positions in clinical operations and project management in Europe in the pharma, biotech and CRO sectors.
He was director of site start up for Quintiles in the Asia-Pacific region.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
